BAX vs. BMY
Compare and contrast key facts about Baxter International Inc. (BAX) and Bristol-Myers Squibb Company (BMY).
Performance
BAX vs. BMY - Performance Comparison
Loading graphics...
BAX vs. BMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BAX Baxter International Inc. | -12.04% | -33.28% | -22.40% | -21.91% | -39.58% | 8.48% | -2.95% | 28.40% | 2.89% | 47.30% |
BMY Bristol-Myers Squibb Company | 13.77% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
Fundamentals
BAX:
$8.64B
BMY:
$123.79B
BAX:
-$1.68
BMY:
$3.46
BAX:
0.77
BMY:
2.57
BAX:
1.41
BMY:
2.22
BAX:
$11.24B
BMY:
$48.19B
BAX:
$3.71B
BMY:
$30.43B
BAX:
$1.67B
BMY:
$13.82B
Returns By Period
In the year-to-date period, BAX achieves a -12.04% return, which is significantly lower than BMY's 13.77% return. Over the past 10 years, BAX has underperformed BMY with an annualized return of -7.23%, while BMY has yielded a comparatively higher 2.72% annualized return.
BAX
- 1D
- 6.33%
- 1M
- -17.53%
- YTD
- -12.04%
- 6M
- -26.14%
- 1Y
- -50.25%
- 3Y*
- -23.72%
- 5Y*
- -26.05%
- 10Y*
- -7.23%
BMY
- 1D
- 1.54%
- 1M
- -2.76%
- YTD
- 13.77%
- 6M
- 37.94%
- 1Y
- 4.47%
- 3Y*
- 0.11%
- 5Y*
- 3.12%
- 10Y*
- 2.72%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BAX vs. BMY — Risk / Return Rank
BAX
BMY
BAX vs. BMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Baxter International Inc. (BAX) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BAX | BMY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -1.05 | 0.16 | -1.20 |
Sortino ratioReturn per unit of downside risk | -1.43 | 0.43 | -1.85 |
Omega ratioGain probability vs. loss probability | 0.79 | 1.05 | -0.26 |
Calmar ratioReturn relative to maximum drawdown | -0.93 | 0.22 | -1.16 |
Martin ratioReturn relative to average drawdown | -1.50 | 0.35 | -1.85 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| BAX | BMY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -1.05 | 0.16 | -1.20 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.79 | 0.13 | -0.92 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.25 | 0.11 | -0.36 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.22 | 0.35 | -0.13 |
Correlation
The correlation between BAX and BMY is 0.36, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
BAX vs. BMY - Dividend Comparison
BAX's dividend yield for the trailing twelve months is around 2.14%, less than BMY's 4.11% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BAX Baxter International Inc. | 2.14% | 2.72% | 3.57% | 3.00% | 2.26% | 1.26% | 1.19% | 1.02% | 1.11% | 0.94% | 1.14% | 87.05% |
BMY Bristol-Myers Squibb Company | 4.11% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
Drawdowns
BAX vs. BMY - Drawdown Comparison
The maximum BAX drawdown since its inception was -81.15%, which is greater than BMY's maximum drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for BAX and BMY.
Loading graphics...
Drawdown Indicators
| BAX | BMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -81.15% | -72.03% | -9.12% |
Max Drawdown (1Y)Largest decline over 1 year | -52.92% | -25.79% | -27.13% |
Max Drawdown (5Y)Largest decline over 5 years | -80.61% | -47.67% | -32.94% |
Max Drawdown (10Y)Largest decline over 10 years | -81.15% | -47.67% | -33.48% |
Current DrawdownCurrent decline from peak | -79.96% | -13.61% | -66.35% |
Average DrawdownAverage peak-to-trough decline | -21.40% | -22.40% | +1.00% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 33.06% | 17.63% | +15.43% |
Volatility
BAX vs. BMY - Volatility Comparison
Baxter International Inc. (BAX) has a higher volatility of 13.66% compared to Bristol-Myers Squibb Company (BMY) at 6.67%. This indicates that BAX's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| BAX | BMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.66% | 6.67% | +6.99% |
Volatility (6M)Calculated over the trailing 6-month period | 34.50% | 19.42% | +15.08% |
Volatility (1Y)Calculated over the trailing 1-year period | 48.14% | 28.60% | +19.54% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 33.11% | 23.66% | +9.45% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 28.95% | 25.08% | +3.87% |
Financials
BAX vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Baxter International Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BAX vs. BMY - Profitability Comparison
BAX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Baxter International Inc. reported a gross profit of 870.00M and revenue of 2.97B. Therefore, the gross margin over that period was 29.3%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported a gross profit of 6.24B and revenue of 12.50B. Therefore, the gross margin over that period was 49.9%.
BAX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Baxter International Inc. reported an operating income of 117.00M and revenue of 2.97B, resulting in an operating margin of 3.9%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported an operating income of 1.47B and revenue of 12.50B, resulting in an operating margin of 11.8%.
BAX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Baxter International Inc. reported a net income of -1.11B and revenue of 2.97B, resulting in a net margin of -37.3%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported a net income of 1.09B and revenue of 12.50B, resulting in a net margin of 8.7%.